Sarepta’s Next-Gen DMD Drug SRP-5051 Shows Advantages, But Safety Concerns Too

 
• By Alaric DeArment
  
MUSCULAR DYSTROPHY words written on label tag with medicine,syringe,keyboard and stethoscope
Sarepta announced data on four patients from the first part of its Phase II trial of SRP-5051 • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Rare Diseases

More from Scrip